<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006315.pub2" GROUP_ID="LIVER" ID="621806081506055581" MERGED_FROM="" MODIFIED="2008-11-12 13:27:18 +0100" MODIFIED_BY="Dimitrinka Nikolova" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 13:19:26 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" REVIEW_NO="11" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.4">
<COVER_SHEET MODIFIED="2008-11-12 13:27:18 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Ischaemic preconditioning for liver transplantation</TITLE>
<CONTACT MODIFIED="2008-11-12 13:27:18 +0100" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="EDD1B9F582E26AA20135ECF1AB0B3200" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kurinchi Selvan</FIRST_NAME><LAST_NAME>Gurusamy</LAST_NAME><SUFFIX>MBBS MS MRCS</SUFFIX><POSITION>Research Fellow</POSITION><EMAIL_1>kurinchi2k@hotmail.com</EMAIL_1><MOBILE_PHONE>+44 (0)7944 629303</MOBILE_PHONE><ADDRESS><DEPARTMENT>University Department of Surgery</DEPARTMENT><ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION><ADDRESS_1>9th Floor, Royal Free Hospital</ADDRESS_1><ADDRESS_2>Pond Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2QG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 830 2757</PHONE_1><FAX_1>+44 207 830 2688</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-12 13:27:18 +0100" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="EDD1B9F582E26AA20135ECF1AB0B3200" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kurinchi Selvan</FIRST_NAME><LAST_NAME>Gurusamy</LAST_NAME><SUFFIX>MBBS MS MRCS</SUFFIX><POSITION>Research Fellow</POSITION><EMAIL_1>kurinchi2k@hotmail.com</EMAIL_1><MOBILE_PHONE>+44 (0)7944 629303</MOBILE_PHONE><ADDRESS><DEPARTMENT>University Department of Surgery</DEPARTMENT><ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION><ADDRESS_1>9th Floor, Royal Free Hospital</ADDRESS_1><ADDRESS_2>Pond Street</ADDRESS_2><CITY>London</CITY><ZIP>NW3 2QG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 830 2757</PHONE_1><FAX_1>+44 207 830 2688</FAX_1></ADDRESS></PERSON><PERSON ID="0BFE5F1D82E26AA200426E0526EF4376" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yogesh</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><POSITION>Registrar</POSITION><EMAIL_1>dryogeshkumar@yahoo.com</EMAIL_1><MOBILE_PHONE>07825794576</MOBILE_PHONE><ADDRESS><DEPARTMENT>General Surgery</DEPARTMENT><ORGANISATION>Leeds Teaching hospital</ORGANISATION><ADDRESS_1>George Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS13EX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1226 360 282</PHONE_1></ADDRESS></PERSON><PERSON ID="7B452FB382E26AA20071EDC0DF8733F6" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Dinesh</FIRST_NAME><LAST_NAME>Sharma</LAST_NAME><SUFFIX>FRCS</SUFFIX><POSITION>Consultant Hepatobiliary Surgeon</POSITION><EMAIL_1>Dinesh.Sharma@royalfree.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>University Department of Surgery</DEPARTMENT><ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION><CITY>London</CITY><ZIP>NW3 2QG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 794 0500 ext: 3934</PHONE_1><FAX_1>+44 207 472 6711</FAX_1></ADDRESS></PERSON><PERSON ID="0BFE5DB682E26AA200426E053932D8DE" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Davidson</LAST_NAME><POSITION>Professor of HPB and Liver Transplant Surgery</POSITION><EMAIL_1>b.davidson@medsch.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>University Department of Surgery</DEPARTMENT><ORGANISATION>Royal Free Hospital and University College School of Medicine</ORGANISATION><ADDRESS_1>Pond Street</ADDRESS_1><CITY>London</CITY><ZIP>NW3 2QG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 207 830 2757</PHONE_1><FAX_1>+44 207 830 2688</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-24 11:52:40 +0100" MODIFIED_BY="dimitrinka nikolova" NOTES="&lt;p&gt;Minor update: 14/11/07&lt;/p&gt;&lt;p&gt;New studies sought but none found: 05/03/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 13/06/06&lt;/p&gt;&lt;p&gt;Conclusions changed: 15/12/06&lt;/p&gt;" NOTES_MODIFIED="2008-10-24 11:52:40 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova">
<UP_TO_DATE>
<DATE DAY="19" MONTH="6" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="6" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="10" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-17 18:37:03 +0100" MODIFIED_BY="dimitrinka nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-17 18:37:03 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="17" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Search update was performed and one new trial was added. Another trial was updated following a new report of the trial.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-24 11:52:18 +0100" MODIFIED_BY="dimitrinka nikolova">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-17 18:30:41 +0100" MODIFIED_BY="dimitrinka nikolova">
<DATE DAY="19" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-09-12 15:32:08 +0100" MODIFIED_BY="dimitrinka nikolova">
<INTERNAL_SOURCES MODIFIED="2008-09-12 15:32:08 +0100" MODIFIED_BY="dimitrinka nikolova">
<SOURCE MODIFIED="2008-09-12 15:32:08 +0100" MODIFIED_BY="dimitrinka nikolova">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-09-12 15:31:57 +0100" MODIFIED_BY="dimitrinka nikolova">
<SOURCE MODIFIED="2008-09-12 15:31:57 +0100" MODIFIED_BY="dimitrinka nikolova">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-12 13:19:26 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<TITLE>No evidence to support or refute the use of ischaemic preconditioning in liver transplantation</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Ischaemic preconditioning is a mechanism for reducing organ ischaemia reperfusion injury by a brief period of organ ischaemia, ie, decrease the injury caused by return of blood supply to the organ after a period of decreased or absent blood supply by exposing the organ to shorter periods of decreased blood supply. There is considerable controversy regarding whether ischaemic preconditioning during donor liver retrieval has beneficial effect on the outcome of liver transplantation. This systematic review includes five randomised clinical trials assessing the advantages and disadvantages of ischaemic preconditioning during donor hepatectomy for liver transplant recipients. In four trials, 270 cadaveric liver donor retrievals were randomised; 131 to ischaemic preconditioning and 139 to no ischaemic preconditioning; and in one trial, 15 living donor liver retrievals were randomised; 10 to ischaemic preconditioning and 5 to no ischaemic preconditioning. All the trials were high bias-risk trials. There was no statistically significant difference in mortality, initial poor function, re-transplant, primary graft non-function, or in any other outcome other than enzyme markers of liver injury, which was in different directions in different trials. There is currently no evidence to support or refute the use of ischaemic preconditioning in donor liver retrievals. Further studies are necessary to identify the optimal ischaemic preconditioning stimulus.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-01 12:03:47 +0100" MODIFIED_BY="dimitrinka nikolova">
<ABS_BACKGROUND MODIFIED="2008-07-01 12:01:34 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Ischaemic preconditioning is a mechanism for reducing organ ischaemia reperfusion injury by a brief period of organ ischaemia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the advantages and disadvantages of ischaemic preconditioning during donor hepatectomy for liver transplant recipients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-07-01 12:03:47 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I>, the<I> Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>) in <I>The Cochrane Library</I>, <I>MEDLINE, EMBASE,</I> and <I>Science Citation Index Expanded</I> until June 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included only randomised clinical trials comparing ischaemic preconditioning versus no ischaemic preconditioning during donor liver retrievals performed in humans in this review (irrespective of language or publication status). </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-06-27 09:44:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Two authors independently identified the trials for inclusion and independently collected the data on the characteristics of the trial, bias-risk of the trials, mortality, initial poor function, primary graft non-function, re-transplantation, intensive therapy unit stay, hospital stay, and liver function tests. We analysed the data with both the fixed-effect and the random-effects models. For each binary outcome we calculated the risk ratio (RR) with 95% confidence intervals (CI) based on available case analysis. For continuous outcomes, we calculated the mean difference (MD) with 95% CI.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-06-27 09:44:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>In four trials, 270 cadaveric liver donor retrievals were randomised; 131 to ischaemic preconditioning and 139 to no ischaemic preconditioning. In one trial, 15 living donor liver retrievals were randomised; 10 to ischaemic preconditioning and 5 to no ischaemic preconditioning. All trials were high bias-risk trials. There was no statistically significant difference in mortality, initial poor function, primary graft non-function,re-transplant, intensive therapy unit stay, or hospital stay between the liver transplant recipients belonging to the two groups. There was no consistent pattern noted in the transaminase activity. There was no statistically significant difference in the bilirubin level or prothrombin activity.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-06-27 09:31:01 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>There is currently no evidence to support or refute the use of ischaemic preconditioning in donor liver retrievals. Further studies are necessary to identify the optimal ischaemic preconditioning stimulus.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND MODIFIED="2008-06-29 06:59:47 +0100" MODIFIED_BY="Kurinchi S Gurusamy">
<P>Around 700 liver transplantations are performed annually in the United Kingdom (<LINK REF="REF-NHS-UK-Transplant" TYPE="REFERENCE">NHS UK Transplant</LINK>). In the USA, the annual incidence of liver transplantation is 21 per one million population (<LINK REF="REF-OPTN_x002f_SRTR-2005" TYPE="REFERENCE">OPTN/SRTR 2005</LINK>). Liver transplant is performed mainly for end-stage liver failure arising as a result of chronic liver disease (for example, cirrhosis due to alcohol consumption, viruses), acutely (example viruses, drug overdose), or as a result of tumour (<LINK REF="REF-Lim-2006" TYPE="REFERENCE">Lim 2006</LINK>). The Model for End-stage Liver Disease score (MELD score) has been suggested as one of the methods of determining the severity of end-stage liver failure (<LINK REF="REF-Kamath-2001" TYPE="REFERENCE">Kamath 2001</LINK>) and is being used as a tool for allocation of livers in some countries (<LINK REF="REF-Shiffman-2006" TYPE="REFERENCE">Shiffman 2006</LINK>). Liver grafts are mainly harvested from cadavers (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>), but there is an increasing interest in live donors (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>) due to shortage of cadaveric organs. Currently, around 40% of liver grafts are retrieved from living donors (<LINK REF="REF-OPTN-2007" TYPE="REFERENCE">OPTN 2007</LINK>). Worldwide, there is a demand for liver transplants in surplus of supply. Recently split liver transplantation (using one cadaveric donor liver for two recipients, ie, an adult and a paediatric recipient) has been suggested as a way to decrease the organ shortage for liver transplant (<LINK REF="REF-Corno-2006" TYPE="REFERENCE">Corno 2006</LINK>).</P>
<P>An alternate approach to the limited supply of organ donors is to make better use of the donor organ pool with the optimisation of the 'marginal donors' in which the donors or the grafts are sub-optimal. Ischaemic preconditioning is one mechanism proposed for the improvement of these grafts. Koti et al (<LINK REF="REF-Koti-2003" TYPE="REFERENCE">Koti 2003</LINK>) and Banga et al (<LINK REF="REF-Banga-2005" TYPE="REFERENCE">Banga 2005</LINK>) have reviewed the various mechanisms of injury mediated by a period of ischaemia followed by reperfusion. These mechanisms involving cytokines and reactive oxygen radicals result in local as well as systemic injury (<LINK REF="REF-Koti-2003" TYPE="REFERENCE">Koti 2003</LINK>; <LINK REF="REF-Banga-2005" TYPE="REFERENCE">Banga 2005</LINK>). Ischaemic preconditioning involves ischaemia and reperfusion for a short period of time before exposure to prolonged ischaemia and reperfusion (<LINK REF="REF-NCBI-2006a" TYPE="REFERENCE">NCBI 2006a</LINK>). Nitric oxide plays a role in both the early (two hours) (<LINK REF="REF-Koti-2003" TYPE="REFERENCE">Koti 2003</LINK>; <LINK REF="REF-Banga-2005" TYPE="REFERENCE">Banga 2005</LINK>) and late ischaemic preconditioning (24 hours), and the effect may last for a few days (<LINK REF="REF-Banga-2005" TYPE="REFERENCE">Banga 2005</LINK>). Other mediators are believed to play a role in ischaemic preconditioning including adenosine (released by the breakdown of adenosine 5'-triphosphate during ischaemia), protein kinase C, tyrosine kinase, and mitogen-activated-protein kinase (<LINK REF="REF-Koti-2003" TYPE="REFERENCE">Koti 2003</LINK>). In liver resections, ischaemic preconditioning has been shown to decrease the elevation of post-operative aspartate amino transferase and alanine amino transferase, which are markers for liver parenchymal injury (<LINK REF="REF-Clavien-2003" TYPE="REFERENCE">Clavien 2003</LINK>). Apoptosis is intrinsically programmed cell death (<LINK REF="REF-NCBI-2006b" TYPE="REFERENCE">NCBI 2006b</LINK>) and is the main mechanism of cell death following ischaemia-reperfusion injury (<LINK REF="REF-Banga-2005" TYPE="REFERENCE">Banga 2005</LINK>). Caspases (cysteine-aspartic acid protease family) are the main mediators of apoptosis (<LINK REF="REF-NCBI-2006c" TYPE="REFERENCE">NCBI 2006c</LINK>) and the level of caspases has been used as a surrogate marker to measure the apoptotic activity (<LINK REF="REF-Kohler-2002" TYPE="REFERENCE">Kohler 2002</LINK>).</P>
<P>In the case of liver transplantation, hepatic pedicle clamping (occluding the portal vein and hepatic artery) can be used to produce the brief period of ischaemia required for ischaemic preconditioning (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>). Recently, ischaemic preconditioning in donor hepatectomies has been shown to be effective in decreasing the markers of liver injury (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>), while other randomised trials report that ischaemic preconditioning is not effective in donor liver retrievals (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>). This is an update of a previously published Cochrane review (<LINK REF="REF-Gurusamy-2008" TYPE="REFERENCE">Gurusamy 2008</LINK>) which concluded that there was no evidence to support or refute the use of ischaemic preconditioning stimulus.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the benefits and harms of ischaemic preconditioning during donor hepatectomy for liver transplantations.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2008-07-01 12:17:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES MODIFIED="2008-07-01 11:36:40 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We have considered for inclusion only randomised clinical trials (irrespective of language, blinding, adequate sample size or publication status).</P>
<P>We have excluded quasi-randomised studies (where the method of allocating participants to a treatment are not strictly random like date of birth, hospital record number, alternation), cohort studies, and case-control studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients who are about to undergo donor liver retrieval (irrespective whether it is living donors or cadaveric donors; adults or children). Most outcomes were measured in transplant recipients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We included trials comparing ischaemic preconditioning versus no ischaemic preconditioning, irrespective of the duration of ischaemic preconditioning. We also included trials comparing two methods of ischaemic preconditioning (for example, different durations of vascular occlusion).</P>
<P>Co-interventions were allowed provided that they were used equally in the intervention arms.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-01 12:17:58 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUBSECTION>
<HEADING LEVEL="4">Outcomes in liver transplant recipients</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<OL>
<LI>Mortality (at 30 days and at maximal follow-up).</LI>
<LI>Liver failure, initial poor function, primary graft non-function (however defined by authors).</LI>
<LI>Re-transplantation.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Intensive care unit stay.</LI>
<LI>Hospital stay.</LI>
<LI>Biochemical markers of liver injury (aspartate aminotransferase and alanine aminotransferase): peak levels, levels on the different days up to one week after transplantation (whichever levels reported by author).</LI>
<LI>Markers of liver function (bilirubin, prothrombin time).</LI>
<LI>Quality of life.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes in living liver transplant donors</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<OL>
<LI>Mortality.</LI>
<LI>Morbidity.</LI>
<LI>Liver failure (however defined by authors).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Intensive care unit stay.</LI>
<LI>Hospital stay.</LI>
<LI>Biochemical markers of liver injury (aspartate aminotransferase and alanine aminotransferase): peak levels, the different days up to one week after liver retrieval (whichever levels reported by author).</LI>
<LI>Markers of liver function (bilirubin, prothrombin time).</LI>
<LI>Quality of life.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We searched <I>The Cochrane Hepato-Biliary Group Controlled Trials Register, </I>the<I> Cochrane Central Register of Controlled Trials </I>(<I>CENTRAL</I>)<I> </I>in<I> The Cochrane Library, MEDLINE, EMBASE, </I>and<I> Science Citation Index Expanded </I>(<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). We have given the search strategies in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> with the time span for the searches.</P>
<P>We also searched the references of the identified trials to identify further relevant trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Trial selection and extraction of data</HEADING>
<P>We did not apply any language or publication status restrictions. KG and YK , independently of each other, identified the trials for inclusion. We have also listed the excluded trials with the reasons for the exclusion.</P>
<P>KG and YK extracted independently the data mentioned above. The authors assessed the bias-risk of the trials independently, without masking of the trial names. Any unclear or missing information was sought by contacting the authors of the individual trials. If there were to be any doubt whether the trials shared the same patients - completely or partially (by identifying common authors and centres), the authors of the trials were to be contacted to clarify whether the trial had been duplicated.</P>
<P>We resolved any differences in opinion through discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality</HEADING>
<P>The authors followed the instructions given in <I>The</I> <I>Cochrane Handbook for Systematic Reviews of Intervention</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and <I>The Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2007" TYPE="REFERENCE">Gluud 2007</LINK>). Because of the risk of overestimation of intervention effects in randomised trials with inadequate methodological quality (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>), we looked at the influence of methodological quality of the trials on the trial results by evaluating the reported randomisation and follow-up procedures in each trial. If information was not available in the published trial, we attempted to contact the authors in order to assess the trials correctly. We assessed the following components below:</P>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Sequence generation</I>
</HEADING>
<UL>
<LI>Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice will be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI>Inadequate, if a system involving dates, names, or admittance numbers were used for the allocation of patients. These trials are known as quasi-randomised and were excluded from the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Allocation concealment</I>
</HEADING>
<UL>
<LI>Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, or sealed envelopes.</LI>
<LI>Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI>Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the trial was quasi-randomised (such trials were excluded).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Blinding</I>
</HEADING>
<P>Patient blinding can be easily achieved. While it is not possible to blind the person who carries out the intervention (ie, occlusion of donor portal triad), it is possible to blind the transplant surgeon who performs the retrieval. The outcome assessors can also be blinded. Thus health-care provider blinding was considered adequate if someone not involved in the donor retrieval otherwise carried out occlusion or no occlusion (based on the randomisation) without the knowledge of others involved in the management of the patient.</P>
<UL>
<LI>Adequate, if the patients, health-care providers, and outcome assessors were blinded and the method of blinding was described.</LI>
<LI>Unclear, if the patients, health-care providers, and outcome assessors were blinded and the method of blinding was not described.</LI>
<LI>Not performed, if the patients, health-care providers, and outcome assessors were not blinded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Incomplete data outcomes</I>
</HEADING>
<UL>
<LI>Adequate, if there were no post-randomisation drop-outs or withdrawals or if the post-randomisation drop-outs were balanced in both groups or reasons for missing data unlikely to be related to true outcome (for example, retrieved livers were not used for transplantation provided blinding was adequate).</LI>
<LI>Unclear, if it is not clear whether there are any drop-outs or withdrawals or if the reasons for these drop-outs are not clear.</LI>
<LI>Inadequate, if the reasons for missing data are likely to be related to true outcomes, "as-treated" analysis was performed, potentially inappropriate application of simple imputation, potential for patients with missing outcomes to induce clinically relevant bias in effect estimate or effect size.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Selective outcome reporting</I>
</HEADING>
<UL>
<LI>Adequate, if all the important outcomes were reported or if the study protocol was available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.</LI>
<LI>Unclear, if there is insufficient information to assess whether the risk of selective outcome reporting is present.</LI>
<LI>Inadequate, if not all the pre-specified outcomes were reported or if the primary outcomes were changed or if some of the important outcomes were incompletely reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Other biases</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Baseline imbalance</HEADING>
<UL>
<LI>Adequate, if there was no baseline imbalance in important characteristics.</LI>
<LI>Unclear, if the baseline characteristics were not reported.</LI>
<LI>Inadequate, if there was an baseline imbalance due to chance or due to imbalanced exclusion after randomisation.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Early stopping</HEADING>
<UL>
<LI>Adequate, if all the important outcomes were reported or if the study protocol was available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way. </LI>
<LI>Unclear, if there is insufficient information to assess whether the risk of selective outcome reporting is present.</LI>
<LI>Inadequate, if not all the pre-specified outcomes were reported or if the primary outcomes were changed or if some of the important outcomes were incompletely reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blocked randomisation in unblinded trials</HEADING>
<UL>
<LI>Adequate, if blocked randomisation was used or blinding was adequate or if the blocks were of variable size or if the blocks were distributed across multiple centres such that it is not possible to predict the block size in a single centre.</LI>
<LI>Unclear, if the method of blocked randomisation was not described.</LI>
<LI>Inadequate, if it was possible to predict future assignments of participants based on previous assignments such as when fixed size blocks were used in a centre when the blinding was inadequate.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical methods</HEADING>
<P>We performed the meta-analyses using the software package RevMan 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>) according to the recommendations of <I>The Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and <I>the Cochrane Hepato-Biliary Group Module</I> (<LINK REF="REF-Gluud-2007" TYPE="REFERENCE">Gluud 2007</LINK>). For dichotomous variables, we calculated the risk ratio with 95% confidence interval (CI). We used a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and a fixed-effect model (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). In case of discrepancy between the two models, we have reported both results. We measured statistical heterogeneity as indicated by I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>) value of &gt; 30. We also explored the heterogeneity by chi-squared test with significance set at P value 0.10.</P>
<P>The analysis was performed on an intention-to-treat basis (<LINK REF="REF-Newell-1992" TYPE="REFERENCE">Newell 1992</LINK>) whenever possible. Otherwise, 'available case analysis' was performed. In case we found 'zero-event' trials for outcomes that are statistically significant without including the 'zero-event' trials, we intended to perform a sensitivity analysis with and without empirical continuity correction factors as suggested by <LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK> et al. We have also reported the results of the risk difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We intended to perform subgroup analyses for:</P>
<UL>
<LI>Each different method of ischaemic preconditioning that we could find. For example, different durations of vascular occlusion.</LI>
<LI>Living donor transplant and cadaveric donor transplant.</LI>
<LI>Adults (18 years of age or above) and paediatric (less than 18 years of age) liver transplant.</LI>
<LI>Suboptimal liver grafts (marginal grafts) (however defined by authors).</LI>
<LI>Bias-risk of the trials.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bias exploration</HEADING>
<P>We used a funnel plot to explore bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Macaskill-2001" TYPE="REFERENCE">Macaskill 2001</LINK>). Asymmetry in funnel plot of trial size against treatment effect was used to assess the risk of bias. We could not perform the linear regression approach described by Egger et al because of the few trials included in the review (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDY_DESCRIPTION MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>We identified a total of 404 bibliographic references through the electronic searches of <I>The Cochrane Hepato-Biliary Group Controlled Trials Register</I> and <I>The Cochrane Central Register of Controlled Trials (CENTRAL)</I> in <I>The Cochrane Library</I> (n = 13), <I>MEDLINE</I> (n = 349), <I>EMBASE</I> (n = 19), and <I>Science Citation Index Expanded</I> (n = 23). We excluded 33 duplicates and 363 clearly irrelevant references through reading abstracts. Eight references of five trials were retrieved for further assessment. No references were identified through scanning reference lists of the identified randomised trials. All the eight references were reports of five randomised clinical trials and their details are shown in the table 'Characteristics of included studies'. So, we were left with no studies for the 'Characteristics of excluded studies'.</P>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Cadaveric transplant</I>
</HEADING>
<P>Four trials randomised 270 cadaveric liver donors to ischaemic preconditioning (n = 131) and no ischaemic preconditioning (n = 139) (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). The proportion of female donors was 45.6%, and the proportion of female recipients was 30%. The mean donor age in the trials was 50 years. The mean recipient age in the trials was 54 years. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Living donor transplant</I>
</HEADING>
<P>One trial randomised 15 patients to three groups; 5 to ischaemic preconditioning 5 minutes before and at the end of liver retrieval; 5 to ischaemic preconditioning 10 minutes before liver retrieval and at every hour, and 5 to no ischaemic preconditioning group (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>). More details regarding donor or recipient were not available.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures</HEADING>
<P>The outcome measures reported by the included trials were mortality, morbidity, initial poor function, primary graft non function, re-transplant, intensive therapy unit stay, hospital stay, and liver function tests. The outcomes measures reported by individual trials are stated in the 'Characteristics of included studies'. The trials also reported other outcomes such as indicators of neutrophil activation, apoptosis, and putative mediators of ischaemic preconditioning which did not fall within the remit of this review.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The bias-risk summary is shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. The bias-risk in individual trials is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. All the trials had adequate random sequence generation and adequate allocation concealment. Two trials reported blinding of recipients only (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). So, none of the trials had adequate blinding. Four of the five trials were free from bias from incomplete outcome data (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>; <LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). Only one trial was free from bias due to selective reporting (<LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). All the four trials, which reported the baseline characteristics were free from bias due to baseline imbalance (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). Three trials reported sample size calculations (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>) and recruited the calculated number of patients. Thus, these three trials were free from early stopping bias. All the trials were free from blocked randomisation in unblinded trials. Because of the lack of blinding in all the trials, all the trials were considered to be of high risk of bias.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Transplant recipients</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Mortality</I>
</HEADING>
<P>There was no statistically significant difference in the mortality between the groups (risk ratio (RR) 0.46; 95% confidence interval (CI) 0.11 to 2.04) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The mortality was 0.7% (1/141) in the ischaemic preconditioning group compared to 2.8% (4/144) in the controls. In two trials, there was no mortality in either group (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>; <LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>). A comparison of overall survival between the groups calculated by the Cox proportional hazard model was reported in one trial (<LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). There was no difference between the groups in the overall survival (hazard ratio (of death) 0.80; 95% CI 0.34 to 1.90) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Another trial which used log rank test to compare the overall survival without providing the exact P-value did not find any difference in the overall survival between the groups (<LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Morbidity</I>
</HEADING>
<P>Only two trials reported surgery related morbidity (<LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). There was no difference in the portal vein thrombosis, hepatic artery thrombosis, or re-operation for haemoperitoneum between the two groups (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Initial poor function or primary graft non-function</I>
</HEADING>
<P>There was no statistically significant difference in the rate of initial poor function (RR 0.72, 95% CI 0.29 to 1.78) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) or in primary graft non-function (RR 0.34, 95% CI 0.07 to 1.64) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) between the groups. The rate of initial poor function and primary graft non-function were 8.4% (7/83) and 0.7% (1/141) in the ischaemic preconditioning group compared to 12.5% (10/80) and 3.5% (5/144) in the controls. A comparison of graft survival between the groups calculated by the Cox proportional hazard model was reported in one trial (<LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). There was no difference between the groups in the graft survival (hazard ratio (of graft failure) 0.90; 95% CI 0.40 to 2.01) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Another trial which used log rank test to compare the graft survival without providing the exact P-value did not find any difference in the graft survival between the groups (<LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Re-transplant</I>
</HEADING>
<P>There was no statistically significant difference in the rate of re-transplantation (RR 0.83, 95% CI 0.20 to 3.5) between the groups (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The re-transplantation rate was 2.7% (3/111) in the ischaemic preconditioning group and 3.5% (4/114) in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Intensive therapy unit stay</I>
</HEADING>
<P>There was no significant difference in the intensive therapy unit stay of the recipients belonging to the two groups (mean difference (MD) 0.05; 95% CI -2.62 to 2.72) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Hospital stay</I>
</HEADING>
<P>There was no significant difference in the hospital stay between the two groups (MD -0.61; 95% CI -3.37 to 2.15) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Biochemical markers of liver injury</I>
</HEADING>
<P>The aspartate transaminase levels on the first, second, and third post-operative days were statistically significantly lower in the ischaemic pre-conditioning group than controls by adopting the fixed-effect model (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). On adopting the random-effects model, the levels were different only on the third post-operative day. There was no difference in the aspartate transaminase levels on the seventh post-operative day.</P>
<P>There was no difference in the alanine transaminase levels on the first, second, third, or seventh post-operative days (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). However, a trend favouring controls was noted on the first and second post-operative days and a trend favouring the ischaemic pre-conditioning group was noted on the third post-operative day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Markers of liver function</I>
</HEADING>
<P>There was no statistically significant difference in the bilirubin level or in the prothrombin activity between the two groups (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> and <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). One trial report stated that there was no difference in the levels of bilirubin and prothrombin activity without reporting the actual value (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>) and could not be included for meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Quality of life</I>
</HEADING>
<P>None of the trials reported quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Subgroup analysis</I>
</HEADING>
<P>All the trials were of high risk of bias and so a subgroup analysis of trials stratified by risk of bias was not performed. Other subgroup analyses were not performed because of the small number of trials included in each outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Variations in analysis</I>
</HEADING>
<P>The random-effects model altered the results of the alanine transaminase levels on the first and second post-operative days as mentioned earlier. None of the other results were altered by adopting random-effects model. We did not perform the sensitivity analysis as suggested by Sweeting et al as we did not find any statistically significant 'zero-event' outcomes (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). Calculating the risk difference did not alter the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Funnel plot</I>
</HEADING>
<P>Visual inspection of funnel plot did not reveal any bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We could not perform the linear regression approach described by Egger et al because of the few trials included in the review (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of different methods of ischaemic preconditioning</HEADING>
<P>The only trial that compared different methods of ischaemic preconditioning stimulus (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>) did not find any mortality, IPF, PGNF, and re-transplantation between the groups (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). There was no difference in alanine transaminase between the two groups on the first post-operative day. The alanine transaminase was statistically significant higher in the repeated stimuli group than the single stimulus group on the second post-operative day (MD 262, 95% CI 93.4 to 430.6) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Living donors</HEADING>
<P>The only trial that utilised liver grafts from living donors did not report on any of the outcomes on living donors.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-01 12:27:55 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>There was no statistical difference in mortality, morbidity, initial poor function, primary graft non function, initial poor function, graft survival, re-transplantation, intensive therapy unit stay, or hospital stay between the two intervention groups. The liver enzyme levels showed considerable variation across the trials as seen on the forest plots. The aspartate transaminase and alanine transaminase did not follow a consistent pattern. While the transaminases are surrogate markers for the extent of liver injury, the reliability of transaminases as determinants of liver function is not clear with one of the trials reporting statistically significant higher transaminase levels (both aspartate transaminase and alanine transaminase) in the ischaemic pre-conditioning group than controls although fewer patients developed initial poor function in the ischaemic pre-conditioning group than controls (difference in initial poor function not statistically significant) (<LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). All the three trials that reported sample size calculations based their calculations on transaminase levels (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). Future trials must base sample size calculations on clinical outcomes.</P>
<P>The preconditioning stimulus was different in the different trials. This included a preconditioning stimulus of five minutes (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>; <LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>), 10 minutes (<LINK REF="STD-Bombuy-2004" TYPE="STUDY">Bombuy 2004</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>; <LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>), and a preconditioning stimulus of five minutes followed by warm reperfusion for 15 minutes and then cold reperfusion (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>). The difference in the reperfusion techniques may be one of the reasons for the wide variation seen in the transaminase levels in the different trials.</P>
<P>Myeloperoxidase secretion is due to neutrophil activation (<LINK REF="REF-Maruyama-2004" TYPE="REFERENCE">Maruyama 2004</LINK>); CD8 is an antigen on the T-lymphocytes (<LINK REF="REF-NCBI-2006d" TYPE="REFERENCE">NCBI 2006d</LINK>) and has been used as a measure of inflammatory response (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>). Inducible nitrogen oxide synthase (iNOS) is a putative mediator of ischaemic reperfusion injury (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>). There was no statistically significant difference in the levels of any of these substances in one trial (<LINK REF="STD-Cescon-2006" TYPE="STUDY">Cescon 2006</LINK>). Another trial showed greater activation of neutrophils following ischaemia-reperfusion (<LINK REF="STD-Koneru-2007" TYPE="STUDY">Koneru 2007</LINK>). There was no statistically significant difference in the apoptosis in the trials that reported this outcome (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>; <LINK REF="STD-Amador-2007" TYPE="STUDY">Amador 2007</LINK>). Further understanding of the pathways activated by ischaemic stimulus and the mechanism of modulation of ischaemic reperfusion injury by ischaemic preconditioning is required.</P>
<P>The potential reasons for the clinical ineffectiveness of ischaemic preconditioning in donor liver retrieval include insufficient sample size because of the choice of a biochemical primary outcome; insufficient duration of ischaemic preconditioning (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>); and lack of effect of ischaemic preconditioning in brain dead patients (<LINK REF="STD-Koneru-2005" TYPE="STUDY">Koneru 2005</LINK>). However, further research is necessary to identify optimal stimulus for ischaemic preconditioning. The research into this is of potential beneficial value as demonstrated by a trend towards fewer patients suffering from primary graft non function and re-transplantation (both of which were not statistically significant) and the lower aspartate transaminase levels.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-27 11:20:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<IMPLICATIONS_PRACTICE>
<P>There is currently no evidence to support or refute the use of ischaemic preconditioning in donor liver retrievals.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-27 11:20:49 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>1. Further studies are necessary to identify the optimal ischaemic preconditioning stimulus.<BR/>2. Further randomised clinical trials are necessary to evaluate the role of ischaemic preconditioning in cadaveric donor liver retrievals, involving a period of warm reperfusion or other optimal ischaemic preconditioning stimulus.<BR/>3. Further randomised clinical trials are necessary to evaluate the role of ischaemic preconditioning in living donor liver retrievals.<BR/>4. Future trials should include clinical outcomes as primary end-points. This may result in the requirement of large multicentric randomised clinical trials.<BR/>5. Trials need to be conducted and reported according to the CONSORT Statement (www.consort-statement.org) (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-10-17 18:33:28 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Martyn Parker, Peterborough District Hospital, Peterborough who inspired me to prepare Cochrane Reviews.<BR/>The Cochrane Hepato-Biliary Group for their support.<BR/>
</P>
<P>Peer Reviewers: K Thorlund, Denmark; A Tahany, Denmark; V Nieuwenhuijs, The Netherlands. <BR/>Contact Editor: C Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>K Gurusamy wrote the review after identifying the trials, extracting data and performing the statistical analysis. Y Kumar independently identified trials and extracted the data from the trials. Mr D Sharma and BR Davidson critically commented on the review and made suggestions to improve the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-12 13:19:26 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUBSECTION>
<HEADING LEVEL="2">Difference between protocol and first edition of the review 2008</HEADING>
<P>None.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Difference between protocol and present second edition of review (Issue 1 2009)</HEADING>
<P>Clinical outcomes have been given more importance. Non-clinical outcomes investigating the role of putative mediators and surrogate markers, which have no direct relation to the clinical outcomes have been removed in order to improve the readability and the focus of the review. Imputations of standard deviations based on guidance from <I>The</I> <I>Cochrane Handbook</I> have been performed. Assessment of risk of bias in the trials was modified based on guidance from the updated <I>Cochrane Handbook </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Difference between first edition from 2008 and present second edition of review (Issue 1 2009)</HEADING>
<P>Search update was performed and one new trial was added. Another trial was updated following a new report of the trial. Clinical outcomes have been given more importance. Non-clinical outcomes investigating the role of putative mediators and surrogate markers, which have no direct relation to the clinical outcomes have been removed in order to improve the readability and the focus of the review. Imputations of standard deviations based on guidance from <I>The</I> <I>Cochrane Handbook</I> have been performed. Assessment of risk of bias in the trials was modified based on guidance from the updated <I>Cochrane Handbook </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-06-26 14:14:50 +0100" MODIFIED_BY="Kurinchi S Gurusamy"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-12 13:19:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES MODIFIED="2008-06-22 07:24:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy">
<INCLUDED_STUDIES MODIFIED="2008-06-22 07:24:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy">
<STUDY DATA_SOURCE="PUB" ID="STD-Amador-2007" MODIFIED="2008-06-22 07:23:53 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Amador 2007" YEAR="">
<REFERENCE MODIFIED="2008-06-22 07:23:53 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Amador A, Grande L, Marti J, Deulofeu R, Miquel R, Sola A, et al</AU>
<TI>Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial</TI>
<SO>American Journal of Transplantation</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>9</NO>
<PG>2180-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-19 23:19:24 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amador A, Marti J, Rodriguez-Laiz G, Bombuy E, Alvarez G, Ferrer J, et al</AU>
<TI>Ischemic preconditioning during donor procurement in orthotopic liver transplantation. Preliminary results of a prospective and randomized trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-19 23:19:27 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amador MA, Marti J, Alvarez G, Rodriguez GP, Bombuy E, Ferrer J, et al</AU>
<TI>Ischemic preconditioning during donor procurement in orthotopic liver transplantation. Preliminary results of a prospective and randomized trial</TI>
<SO>Liver Transplantation</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>6</NO>
<PG>C35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bombuy-2004" MODIFIED="2008-06-22 07:16:18 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Bombuy 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-06-20 13:27:19 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bombuy E, Fondevila C, Rodriguez-Laiz G, Ferrer J, Amador A, Valentini M, et al</AU>
<TI>Ischemic preconditioning in adult living donor liver transplantation, a pilot study [EASL abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cescon-2006" MODIFIED="2008-06-22 07:16:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Cescon 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-06-20 13:27:33 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Ercolani G, et al</AU>
<TI>Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study</TI>
<SO>Liver Transplantation</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>628-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Koneru-2005" MODIFIED="2008-06-22 07:16:32 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Koneru 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al</AU>
<TI>Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy</TI>
<SO>Liver Transplantation</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koneru B, Fisher A, Skurnick J, Klein K, He Y, Wilson D, et al</AU>
<TI>Ischemic preconditioning in cadaver donor liver transplantation: a prospective randomized clinical trial of safety and efficacy</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>s8</NO>
<PG>507</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koneru-2007" MODIFIED="2008-06-22 07:24:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NAME="Koneru 2007" YEAR="">
<REFERENCE MODIFIED="2008-06-22 07:24:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, et al</AU>
<TI>The ischemic preconditioning paradox in deceased donor liver transplantation-evidence from a prospective randomized single blind clinical trial</TI>
<SO>American Journal of Transplantation</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>12</NO>
<PG>2788-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-12 13:19:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-12 13:19:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Banga-2005" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Banga 2005" TYPE="JOURNAL_ARTICLE">
<AU>Banga NR, Homer-Vanniasinkam S, Graham A, Al-Mukhtar A, White SA, Prasad KR</AU>
<TI>Ischaemic preconditioning in transplantation and major resection of the liver</TI>
<SO>The British Journal of Surgery</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>5</NO>
<PG>528-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clavien-2003" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Clavien 2003" TYPE="JOURNAL_ARTICLE">
<AU>Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, et al</AU>
<TI>A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning</TI>
<SO>Annals of Surgery</SO>
<YR>2003</YR>
<VL>238</VL>
<NO>6</NO>
<PG>843-50; discussion 851-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corno-2006" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Corno 2006" TYPE="JOURNAL_ARTICLE">
<AU>Corno V, Colledan M, Dezza MC, Guizzetti M, Lucianetti A, Maldini G, et al</AU>
<TI>Extended right split liver graft for primary transplantation in children and adults</TI>
<SO>Transplantation International</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>6</NO>
<PG>492-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods for combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey SG, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2007" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gluud 2007" NOTES="&lt;p&gt;Gluud C, Nikolova D, Klingenberg SL, Als-Nielsen B, D'Amico G, Davidson B, Fingerhut A, Gluud LL, Gurusamy K, Khan S, Koretz R, Liu JP, Myers R, Pagliaro L, Simonetti R, Sutton R. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2007, Issue 2. Art. No.: LIVER.&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 13:16:38 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Als-Nielsen B, D'Amico G, Davidson B, et al</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2007, Issue 2. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-11-12 13:19:24 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008]</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Colloboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamath-2001" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kamath 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al</AU>
<TI>A model to predict survival in patients with end-stage liver disease</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>2</NO>
<PG>464-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohler-2002" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Kohler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kohler C, Orrenius S, Zhivotovsky B</AU>
<TI>Evaluation of caspase activity in apoptotic cells</TI>
<SO>Journal of Immunological Methods</SO>
<YR>2002</YR>
<VL>265</VL>
<NO>1-2</NO>
<PG>97-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koti-2003" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Koti 2003" TYPE="JOURNAL_ARTICLE">
<AU>Koti RS, Seifalian AM, Davidson BR</AU>
<TI>Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications</TI>
<SO>Digestive Surgery</SO>
<YR>2003</YR>
<VL>20</VL>
<NO>5</NO>
<PG>383-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lim-2006" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lim 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lim SG, Wai CT, Da Costa M, Sutedja DS, Lee YM, Lee KH, et al</AU>
<TI>Referral patterns and waiting times for liver transplantation in Singapore</TI>
<SO>Singapore Medical Journal</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>7</NO>
<PG>599-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macaskill-2001" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Macaskill 2001" TYPE="JOURNAL_ARTICLE">
<AU>Macaskill P, Walter SD, Irwig L</AU>
<TI>A comparison of methods to detect publication bias in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>641-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maruyama-2004" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Maruyama 2004" TYPE="JOURNAL_ARTICLE">
<AU>Maruyama Y, Lindholm B, Stenvinkel P</AU>
<TI>Inflammation and oxidative stress in ESRD - the role of myeloperoxidase</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>Suppl 8</NO>
<PG>S72-S76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG (for the CONSORT Group)</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9263</NO>
<PG>1191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCBI-2006a" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="NCBI 2006a" TYPE="OTHER">
<AU>NCBI</AU>
<TI>MeSH. Ischemic preconditioning</TI>
<SO>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=mesh&amp;list_uids=68019194&amp;dopt=Full</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCBI-2006b" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="NCBI 2006b" TYPE="OTHER">
<AU>NCBI</AU>
<TI>MeSH. Apoptosis</TI>
<SO>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=mesh&amp;list_uids=68017209&amp;dopt=Full</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCBI-2006c" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="NCBI 2006c" TYPE="OTHER">
<AU>NCBI</AU>
<TI>Entrez Protein. NP 004337. caspase 3 preproprotein [Homo sapiens]. Comment</TI>
<SO>http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;val=14790119</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCBI-2006d" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="NCBI 2006d" TYPE="OTHER">
<AU>NCBI</AU>
<TI>MeSH. Antigens, CD8</TI>
<SO>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=mesh&amp;list_uids=68016827&amp;dopt=Full</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-1992" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Newell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newell DJ</AU>
<TI>Intention-to-treat analysis: implications for quantitative and qualitative research</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHS-UK-Transplant" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="NHS UK Transplant" TYPE="OTHER">
<TI>NHS UK Transplant - Annual Report 2003-2004</TI>
<SO>http://www.uktransplant.org.uk/ukt/about_us/annual_report/archive_annual_reports/ann_report_2003_2004.pdf</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OPTN-2007" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="OPTN 2007" TYPE="OTHER">
<TI>The organ procurement and transplantation network. Donors recovered in the US by donor type</TI>
<SO>http://www.optn.org/latestData/rptData.asp</SO>
<YR>2007 (last accessed on 09/09/07)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OPTN_x002f_SRTR-2005" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="OPTN/SRTR 2005" TYPE="OTHER">
<TI>The Organ Procurement and Transplant Network/ Scientific Registry of Transplant Recipients 2005 Annual Report</TI>
<SO>http://www.ustransplant.org/annual_reports/current/905_li.pdf</SO>
<YR>(accessed 19 April 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<PB>Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Royle 2003" NOTES="&lt;p&gt;'International Journal of Technology Assessment in Health Care' 2003;19:4:591-603 with a title 'Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches' by Royle P et al.&lt;/p&gt;" NOTES_MODIFIED="2008-11-12 13:16:38 +0100" NOTES_MODIFIED_BY="dimitrinka nikolova" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shiffman-2006" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Shiffman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, et al</AU>
<TI>Liver and intestine transplantation in the United States, 1995-2004</TI>
<SO>American Journal of Transplantation</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>5 Pt 2</NO>
<PG>1170-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Sweeting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1351-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Gurusamy-2008" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gurusamy 2008" TYPE="COCHRANE_REVIEW">
<AU>Gurusamy KS, Kumar Y, Sharma D, Davidson BR</AU>
<TI>Ischaemic preconditioning for liver transplantation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-06-27 11:12:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-06-27 11:12:52 +0100" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD006315.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Amador-2007">
<CHAR_METHODS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial</P>
<P>Generation of the allocation sequence: computer generated (adequate).<BR/>Allocation concealment: adequate (sealed envelope).<BR/>Blinding: inadequate.<BR/>Incomplete outcome data addressed: yes.<BR/>Free of selective reporting: no.<BR/>Free from baseline imbalance: yes.<BR/>Free from early stopping bias: yes.<BR/>Free from bias due to blocked randomisation: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Country: Spain.<BR/>Number randomised: 60.<BR/>Donor mean age: 56.5 years.<BR/>Recipient mean age: 54.5 years.<BR/>Donor females: 31 (51.7%).<BR/>Recipient females: 28 (46.7%).<BR/>Living or cadaveric donors: cadaveric.</P>
<P>Inclusion criteria</P>
<OL>
<LI>Adult cadaveric donor liver transplantation.</LI>
</OL>
<P>Exclusion criteria</P>
<OL>
<LI>Liver procurement associated with pancreas.</LI>
<LI>Donor age &lt; 35 years.</LI>
<LI>Transplantation for acute liver failure.</LI>
<LI>Emergency re-transplantation.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Participants were randomly assigned to two groups.</P>
<P>Group 1: IPC (n = 30), 10 minutes clamping.</P>
<P>Group 2: No IPC (n = 30).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The outcomes reported were morbidity, liver enzymes, and PGNF.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-01 12:56:04 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Bombuy-2004">
<CHAR_METHODS MODIFIED="2008-07-01 12:56:04 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial</P>
<P>Generation of the allocation sequence: random number table (adequate).<BR/>Allocation concealment: sealed envelope technique (adequate).<BR/>Blinding: inadequate.<BR/>Incomplete outcome data addressed: yes.<BR/>Free of selective reporting: no.<BR/>Free from baseline imbalance: unclear.<BR/>Free from early stopping bias: unclear.<BR/>Free from bias due to blocked randomisation: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Spain.<BR/>Number randomised: 15.<BR/>Donor mean age: not stated.<BR/>Recipient mean age: not stated.<BR/>Donor females: not stated.<BR/>Recipient females: not stated.<BR/>Living or cadaveric donors: Living.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Participants were randomly assigned to three groups.</P>
<P>Group 1: IPC (n = 5), 5 minutes clamping.</P>
<P>Group 2: IPC (n = 5), 10 minutes on and 50 minutes off for first 3 hours.</P>
<P>Group 3: No IPC (n = 5).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>The outcomes reported were liver function tests, adenosine, PGNF, IPF and re-transplantation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Further information regarding allocation sequence generation, allocation concealment, drop-outs, mortality, re-transplantation, initial poor function, primary graft non-function, and liver enzymes were sought from the author. The authors replied to all the questions on 21/01/2007.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Cescon-2006">
<CHAR_METHODS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial</P>
<P>Generation of the allocation sequence: computer generated (adequate).<BR/>Allocation concealment: sealed envelope technique (adequate).<BR/>Blinding: inadequate.<BR/>Incomplete outcome data addressed: no.<BR/>Free of selective reporting: no.<BR/>Free from baseline imbalance: unclear.<BR/>Free from early stopping bias: unclear.<BR/>Free from bias due to blocked randomisation: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Country: Italy.<BR/>Number randomised: 47.<BR/>Donor median age: 68 years (IPC); 63 years (control).<BR/>Recipient median age: 54 years (IPC); 53.5 years (control).<BR/>Donor females: 23 (48.9%).<BR/>Recipient females: 9 (19.1%).<BR/>Living or cadaveric donors: cadaveric.</P>
<P>Inclusion criteria</P>
<OL>
<LI>Age &gt; 18 years.</LI>
<LI>Undergoing primary, isolated, non-urgent OLT .</LI>
</OL>
<P>Exclusion criteria</P>
<OL>
<LI>Re-transplantation.</LI>
<LI>Patients with fulminant hepatic failure.</LI>
<LI>Recipients of split liver transplantation and of combined or domino transplantation.</LI>
<LI>Haemodynamic stability of donor (in the ITU).</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-22 06:11:21 +0100" MODIFIED_BY="Kurinchi S Gurusamy">
<P>Participants were randomly assigned to two groups.</P>
<P>Group 1: IPC (n = 23), 10 minutes clamping followed by 15 minutes warm perfusion, followed by cold perfusion.</P>
<P>Group 2: No IPC (n = 24).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The outcomes reported were mortality, PGNF, IPF, re-transplantation, ITU stay, and liver function tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Further information on the liver function tests was sought from the authors. The authors replied to all the questions on 30/09/2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-12 15:18:35 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Koneru-2005">
<CHAR_METHODS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial</P>
<P>Generation of the allocation sequence: computer generated (adequate).<BR/>Allocation concealment: sealed envelope technique (adequate).<BR/>Blinding: inadequate.<BR/>Incomplete outcome data addressed: yes.<BR/>Free of selective reporting: no.<BR/>Free from baseline imbalance: yes.<BR/>Free from early stopping bias: yes.<BR/>Free from bias due to blocked randomisation: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-12 15:18:35 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Country: USA.<BR/>Number randomised: 62.<BR/>Donor mean age: 46.5 years.<BR/>Recipient mean age: 53.1 years.<BR/>Donor females: 28 (45.2%).<BR/>Recipient females: 20 (32.3%).<BR/>Living or cadaveric donors: cadaveric.</P>
<P>Inclusion criteria</P>
<OL>
<LI>Cadaveric donors.</LI>
<LI>Adult recipients ( &gt; 18 years).</LI>
</OL>
<P>Exclusion criteria</P>
<OL>
<LI>Combined liver and intestine donors.</LI>
<LI>Donors for paediatric liver recipients.</LI>
<LI>Donors for recipients at another transplant centre.</LI>
<LI>Donor livers recovered outside the local organ recovery network for use by local recipients.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Participants were randomly assigned to two groups.</P>
<P>Group 1: IPC (n = 28), 5 minutes of clamping.</P>
<P>Group 2: No IPC (n = 34).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The outcomes reported were mortality, PGNF, re-transplantation, hospital stay, and liver function tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Further information on the allocation concealment, re-transplantation, and PGNF was sought from the authors. The authors replied to all the questions on 17/09/2006.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" STUDY_ID="STD-Koneru-2007">
<CHAR_METHODS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Randomised clinical trial</P>
<P>Generation of the allocation sequence: computer generated (adequate).<BR/>Allocation concealment: sealed envelope technique (adequate).<BR/>Blinding: inadequate.<BR/>Incomplete outcome data addressed: yes.<BR/>Free of selective reporting: yes.<BR/>Free from baseline imbalance: yes.<BR/>Free from early stopping bias: yes.<BR/>Free from bias due to blocked randomisation: yes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Country: USA.<BR/>Number randomised: 101.<BR/>Donor mean age: 46 years.<BR/>Recipient mean age: 53 years.<BR/>Donor females: 41 (40.6%).<BR/>Recipient females: 24 (23.8%).<BR/>Living or cadaveric donors: cadaveric.</P>
<P>Inclusion criteria</P>
<OL>
<LI>Cadaveric donors.</LI>
<LI>Adult recipients ( &gt; 18 years).</LI>
</OL>
<P>Exclusion criteria</P>
<OL>
<LI>combined liver and intestine donors. </LI>
<LI>Cardiac non-beating donors.</LI>
<LI>Livers from other organ networks.</LI>
<LI>Reduced size livers.</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>Participants were randomly assigned to two groups.</P>
<P>Group 1: IPC (n = 50), 10 minutes of clamping.</P>
<P>Group 2: No IPC (n = 51).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova">
<P>The outcomes reported were mortality, morbidity, IPF, PGNF, re-transplantation, ITU stay, hospital stay, and liver function tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IPC = ischaemic pre-conditioning.<BR/>IPF = initial poor function.<BR/>ITU = intensive therapy unit.<BR/>PGNF = primary graft non-function.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate ("Donors were distributed according to a computer-generated table of simple random numbers enclosed in numbered and sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>A - Adequate ("random number table")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>A - Adequate ("blind extraction of computer-generated sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate ("Randomization was performed according to a computer-generated table of simple random numbers enclosed in numbered and sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate ("The biostatistician provided a computer-generated sequence allocation to IPC and No IPC")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate ("Donors were distributed according to a computer-generated table of simple random numbers enclosed in numbered and sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>A - Adequate ("closed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>A - Adequate ("blind extraction of computer-generated sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate ("Randomization was performed according to a computer-generated table of simple random numbers enclosed in numbered and sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate ("Participants were assigned to IPC or No IPC by the study coordinator, via sequentially numbered opaque and sealed envelopes")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>C - Inadequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>C - Inadequate ("The pathologist and the laboratory technicians who evaluated and processed the samples did not have the information about the group affiliation"). <BR/>Comment by authors of review: The clinicians were not blinded and so no aspect of blinding was considered adequate.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>C- Inadequate ("Hematoxylin &amp; eosin evaluation was performed by an experienced pathologist without knowledge of the study group assignment")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>C - Inadequate ("concealed only to the recipients")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>C - Inadequate ("Only the subjects were blinded to the group assignment throughout the length of their participation")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate (no drop-outs)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>A - Adequate (no drop-outs)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>C - Inadequate (6 patients - 3 in each group were excluded post-randomisation and the outcomes could have been affected if these patients were included for analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate (no drop-outs)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate (no patient excluded from analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>C- Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="NO" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate (all the important outcomes reported)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-06-19 22:12:03 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova" NO="7">
<NAME>Free from baseline imbalance?</NAME>
<DESCRIPTION>
<P>Were the participants matched between the groups for important characteristics?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova" NO="8">
<NAME>Free from early stopping bias?</NAME>
<DESCRIPTION>
<P>Was the trial free from bias due to early stopping because of formal or informal stopping rules?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2008-09-12 15:34:40 +0100" MODIFIED_BY="dimitrinka nikolova" NO="9">
<NAME>Free from bias due to blocked randomisation</NAME>
<DESCRIPTION>
<P>Is the trial free from bias due to blocked randomisation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-12 15:30:42 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Amador-2007">
<DESCRIPTION>
<P>A - Adequate (simple random numbers).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-12 15:17:39 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Bombuy-2004">
<DESCRIPTION>
<P>A - Adequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-12 15:18:20 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="UNKNOWN" STUDY_ID="STD-Cescon-2006">
<DESCRIPTION>
<P>A - Adequate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2005">
<DESCRIPTION>
<P>A - Adequate (simple random numbers)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:44:14 +0100" MODIFIED_BY="dimitrinka nikolova" RESULT="YES" STUDY_ID="STD-Koneru-2007">
<DESCRIPTION>
<P>A - Adequate ("Group assignments were balanced over block lengths of 12, 16 and 20, where the length was selected at random")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-22 05:40:27 +0100" MODIFIED_BY="Kurinchi S Gurusamy"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-01 12:45:07 +0100" MODIFIED_BY="dimitrinka nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-01 12:45:07 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<NAME>Ischaemic preconditioning versus control</NAME>
<DICH_OUTCOME CHI2="1.901683149056652" CI_END="2.040577547182737" CI_START="0.10533928589480601" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4636302207936885" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.30975310372757475" LOG_CI_START="-0.9774096300928008" LOG_EFFECT_SIZE="-0.33382826318261305" METHOD="MH" MODIFIED="2008-06-20 15:26:44 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.38641575933526484" P_Q="0.0" P_Z="0.30932413183266805" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="144" WEIGHT="100.0" Z="1.016641261695799">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.82882080128427" CI_START="0.12706691849706478" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8502100114756685" LOG_CI_START="-0.895967502036344" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="147" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="9.21708639991234"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="148" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.119120928192492" CI_START="0.010536903027225111" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6148045420597888" LOG_CI_START="-1.9772870168109633" LOG_EFFECT_SIZE="-0.6812412373755872" ORDER="146" O_E="0.0" SE="1.5226074127408329" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" VAR="2.3183333333333334" WEIGHT="45.144912979162484"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="149" O_E="0.0" SE="0.0" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.144054899529164" CI_START="0.010034617581008614" EFFECT_SIZE="0.20392156862745098" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6174255002132006" LOG_CI_START="-1.9984991738115123" LOG_EFFECT_SIZE="-0.690536836799156" ORDER="150" O_E="0.0" SE="1.5366071025580923" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" VAR="2.361161387631976" WEIGHT="45.638000620925176"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.9044324985219212" CI_START="0.33608739013161154" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.27976558395995826" LOG_CI_START="-0.4735477817851893" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.0968910989126155" MODIFIED="2008-06-20 15:26:44 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6141343395879252" Q="0.0" RANDOM="NO" SCALE="3.834269881767063" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="0.504180790960452">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.9044324985219212" CI_START="0.33608739013161154" EFFECT_SIZE="0.8000348418100656" ESTIMABLE="YES" ESTIMATE="-0.2231" LOG_CI_END="0.27976558395995826" LOG_CI_START="-0.4735477817851893" LOG_EFFECT_SIZE="-0.0968910989126155" ORDER="188" SE="0.4425" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="4.492367109504739" CI_END="1.0980714797496272" CI_START="0.10118750296332779" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="55.480040894955046" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.04063061174468997" LOG_CI_START="-0.9948731211840147" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" MODIFIED="2008-07-01 12:45:07 +0100" MODIFIED_BY="dimitrinka nikolova" NO="3" P_CHI2="0.10580236205957994" P_Q="0.0" P_Z="0.07089402523853175" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90" TOTAL_2="90" WEIGHT="300.0" Z="1.8061556820548612">
<NAME>Morbidity</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.95416281504153" CI_START="0.25011464551267176" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-06-19 21:59:02 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="1.0" P_Z="0.2922772002054833" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.053139231306288">
<NAME>Portal vein thrombosis</NAME>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="190" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6515870907376713" CI_START="0.007696584184088997" DF="0.0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2008-06-19 21:59:02 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="1.0" P_Z="0.19166919687502434" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.3056570887327816">
<NAME>Hepatic artery thrombosis</NAME>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="191" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3074563269125963" CI_START="0.004525703567694904" DF="0.0" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.11642719100191871" LOG_CI_START="-2.344313895615592" LOG_EFFECT_SIZE="-1.1139433523068367" MODIFIED="2008-07-01 12:45:07 +0100" MODIFIED_BY="dimitrinka nikolova" NO="3" P_CHI2="1.0" P_Z="0.07598097608985668" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.774497010849948">
<NAME>Re-operation for haemoperitoneum</NAME>
<DICH_DATA CI_END="1.3074563269125963" CI_START="0.004525703567694904" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11642719100191871" LOG_CI_START="-2.344313895615592" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="192" O_E="0.0" SE="1.4454514951439552" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.0893300248138957" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20231540275347742" CI_END="1.7820116810036606" CI_START="0.28925107325237004" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7179476243282437" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2509105464903095" LOG_CI_START="-0.5387250209441738" LOG_EFFECT_SIZE="-0.14390723722693216" METHOD="MH" MODIFIED="2008-06-20 13:50:04 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.6528583858324815" P_Q="0.0" P_Z="0.4749874281787321" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="80" WEIGHT="100.0" Z="0.7143877852306874">
<NAME>Initial poor function (IPF)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="152" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.802070662385297" CI_START="0.16007579676120917" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8326411392292543" LOG_CI_START="-0.795674327841228" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="153" O_E="0.0" SE="0.956480565648758" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" VAR="0.9148550724637682" WEIGHT="19.81574682248571"/>
<DICH_DATA CI_END="1.816393723234817" CI_START="0.22374347852085213" EFFECT_SIZE="0.6375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2592099924751341" LOG_CI_START="-0.6502496142631486" LOG_EFFECT_SIZE="-0.19551981089400725" ORDER="151" O_E="0.0" SE="0.5342210748957262" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" VAR="0.2853921568627451" WEIGHT="80.1842531775143"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9554227341210648" CI_END="1.6393461014617916" CI_START="0.07009056268987324" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33897299404953635" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.21467065222033116" LOG_CI_START="-1.1543404534687878" LOG_EFFECT_SIZE="-0.4698349006242283" METHOD="MH" MODIFIED="2008-06-20 13:50:17 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="5" P_CHI2="0.6202012256846903" P_Q="0.0" P_Z="0.1785311259497956" Q="0.0" RANDOM="NO" SCALE="150.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="144" WEIGHT="100.0" Z="1.3452914736435393">
<NAME>Primary graft non function (PGNF)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="156" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="58.72988963669961"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.112670492455225" CI_START="0.014861107907323728" EFFECT_SIZE="0.3472222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9091638368536604" LOG_CI_START="-1.8279488123721221" LOG_EFFECT_SIZE="-0.45939248775923086" ORDER="158" O_E="0.0" SE="1.6077935190813526" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" VAR="2.585" WEIGHT="24.65628019733162"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="157" O_E="0.0" SE="0.0" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.863592387135773" CI_START="0.06558413596429075" EFFECT_SIZE="1.02" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2004015422025431" LOG_CI_START="-1.1832011986787079" LOG_EFFECT_SIZE="0.008600171761917567" ORDER="154" O_E="0.0" SE="1.4001400490175064" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" VAR="1.9603921568627451" WEIGHT="16.61383016596877"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="1.1423589683347665E-33" CI_END="2.0126680140178532" CI_START="0.402499585453941" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.9000544657400421" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.30377214469960745" LOG_CI_START="-0.39523456258843226" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.045731208944412405" MODIFIED="2008-06-20 13:50:17 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.7976003191766632" Q="0.0" RANDOM="NO" SCALE="2.757506934078277" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="0.2564539698002922">
<NAME>Graft survival</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="2.0126680140178532" CI_START="0.402499585453941" EFFECT_SIZE="0.9000544657400421" ESTIMABLE="YES" ESTIMATE="-0.1053" LOG_CI_END="0.30377214469960745" LOG_CI_START="-0.39523456258843226" LOG_EFFECT_SIZE="-0.045731208944412405" ORDER="189" SE="0.4106" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.2770761754864789" CI_END="3.4970725315673503" CI_START="0.19563870400047859" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8271413046581032" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.5437046399537389" LOG_CI_START="-0.7085452228048801" LOG_EFFECT_SIZE="-0.0824202914255706" METHOD="MH" MODIFIED="2008-06-20 16:17:54 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="7" P_CHI2="0.8706300990234613" P_Q="0.0" P_Z="0.7964062042896938" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="114" WEIGHT="100.0" Z="0.25800091114971374">
<NAME>Re-transplant</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="161" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.130850210615554" CI_START="0.13498043138236007" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9101359604124011" LOG_CI_START="-0.869729188235827" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="159" O_E="0.0" SE="1.0455015987905485" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" VAR="1.093073593073593" WEIGHT="43.6606269476777"/>
<DICH_DATA CI_END="9.997878503255016" CI_START="0.015354989712972516" EFFECT_SIZE="0.391812865497076" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9999078547923942" LOG_CI_START="-1.8137504701750489" LOG_EFFECT_SIZE="-0.40692130769132745" ORDER="162" O_E="0.0" SE="1.65275682791921" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" VAR="2.731605132233569" WEIGHT="32.635831359606186"/>
<DICH_DATA CI_END="16.774690754830228" CI_START="0.062071655142653254" EFFECT_SIZE="1.0204081632653061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2246545225990781" LOG_CI_START="-1.207106673984068" LOG_EFFECT_SIZE="0.008773924307505152" ORDER="160" O_E="0.0" SE="1.4284285642849999" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" VAR="2.040408163265306" WEIGHT="23.70354169271611"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0013478513663512776" CI_END="2.7182133543439524" CI_START="-2.6197514906090826" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.049230931867434685" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-06-20 16:17:54 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="8" P_CHI2="0.9707137706911517" P_Q="1.0" P_Z="0.9711606213884061" Q="0.0" RANDOM="NO" SCALE="5.107262590106792" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="0.036152674732111756">
<NAME>ITU stay</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.903878927000859" CI_START="-3.7038789270008596" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.7" ORDER="194" SD_1="8.0" SD_2="7.0" SE="1.9407902170679516" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="49.230931867434855"/>
<CONT_DATA CI_END="3.745813216030697" CI_START="-3.745813216030697" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.0" ORDER="193" SD_1="8.0" SD_2="11.0" SE="1.9111643099450772" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="50.769068132565145"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4270218078981923" CI_END="2.1516811070502264" CI_START="-3.370656727881328" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6094878104155506" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-06-24 06:39:13 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="9" P_CHI2="0.8077434621229151" P_Q="1.0" P_Z="0.6652810534045182" Q="0.0" RANDOM="NO" SCALE="7.652667178725868" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="115" UNITS="" WEIGHT="100.0" Z="0.43263349441404164">
<NAME>Hospital stay</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.0848473465372965" CI_START="-7.0848473465372965" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="24.0" ORDER="187" SD_1="14.0" SD_2="14.0" SE="3.6147844564602556" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="15.18885224678609"/>
<CONT_DATA CI_END="3.001790087993748" CI_START="-7.001790087993748" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="10.0" MODIFIED="2008-06-24 06:39:13 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="83" SD_1="10.0" SD_2="10.0" SE="2.551980611606759" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="30.474390520777526"/>
<CONT_DATA CI_END="3.745813216030697" CI_START="-3.745813216030697" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.0" ORDER="186" SD_1="8.0" SD_2="11.0" SE="1.9111643099450772" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="54.33675723243638"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="32.19915664689291" CI_END="9.760337956858585" CI_START="-42.78667529091078" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.513168667026097" ESTIMABLE="YES" I2="62.73194316361714" I2_Q="74.31906929651194" ID="CMP-001.10" MODIFIED="2008-06-24 08:23:52 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="10" P_CHI2="0.0012891471876312899" P_Q="0.008556554593722843" P_Z="0.21800234770310034" Q="11.681819614086383" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="418" TOTAL_2="437" UNITS="" WEIGHT="400.0" Z="1.2318574875187738">
<NAME>AST (IU/L)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.240022219644517" CI_END="-18.429054335290914" CI_START="-489.72777530414237" DF="2.0" EFFECT_SIZE="-254.07841481971664" ESTIMABLE="YES" I2="82.20644086891092" ID="CMP-001.10.01" MODIFIED="2008-06-24 06:38:47 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.003624608244546912" P_Z="0.034579908988338084" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="105" WEIGHT="100.0" Z="2.1132437672309528">
<NAME>First post-operative day</NAME>
<CONT_DATA CI_END="-9.272790692922001" CI_START="-798.727209307078" EFFECT_SIZE="-404.0" ESTIMABLE="YES" MEAN_1="918.0" MEAN_2="1322.0" ORDER="329" SD_1="780.0" SD_2="780.0" SE="201.39513400278568" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="35.64005803984574"/>
<CONT_DATA CI_END="-336.5789911055269" CI_START="-1337.421008894473" EFFECT_SIZE="-837.0" ESTIMABLE="YES" MEAN_1="398.0" MEAN_2="1235.0" MODIFIED="2008-06-22 06:18:46 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="176" SD_1="875.0" SD_2="875.0" SE="255.3215328657721" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="22.174889414115743"/>
<CONT_DATA CI_END="541.8164488793435" CI_START="-183.8164488793435" EFFECT_SIZE="179.0" ESTIMABLE="YES" MEAN_1="699.0" MEAN_2="520.0" ORDER="177" SD_1="956.0" SD_2="903.0" SE="185.11383461185682" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="42.18505254603852"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.626785616587796" CI_END="-17.812040501349173" CI_START="-345.91335862596566" DF="2.0" EFFECT_SIZE="-181.8626995636574" ESTIMABLE="YES" I2="76.81639385874675" ID="CMP-001.10.02" MODIFIED="2008-06-22 06:20:22 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="0.013388083687870034" P_Z="0.02979763651784166" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="105" WEIGHT="100.0" Z="2.1727699438294565">
<NAME>Second post-operative day</NAME>
<CONT_DATA CI_END="-5.500040247431286" CI_START="-506.4999597525687" EFFECT_SIZE="-256.0" ESTIMABLE="YES" MEAN_1="500.0" MEAN_2="756.0" MODIFIED="2008-06-20 18:04:28 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="330" SD_1="495.0" SD_2="495.0" SE="127.80845042484475" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="42.88847835155069"/>
<CONT_DATA CI_END="-113.61367942788189" CI_START="-692.3863205721182" EFFECT_SIZE="-403.0" ESTIMABLE="YES" MEAN_1="283.0" MEAN_2="686.0" MODIFIED="2008-06-22 06:20:22 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="179" SD_1="506.0" SD_2="506.0" SE="147.64879500580648" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="32.13660265009812"/>
<CONT_DATA CI_END="558.2660242588445" CI_START="-98.26602425884448" EFFECT_SIZE="230.0" ESTIMABLE="YES" MEAN_1="583.0" MEAN_2="353.0" ORDER="178" SD_1="1003.0" SD_2="636.0" SE="167.48574302801734" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="24.9749189983512"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1986028361894998" CI_END="-1.7373610193492084" CI_START="-265.5218587240464" DF="2.0" EFFECT_SIZE="-133.62960987169782" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" MODIFIED="2008-06-22 06:21:02 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="3" P_CHI2="0.9054698160025829" P_Z="0.04705756146822793" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="88" WEIGHT="100.0" Z="1.9857817642480966">
<NAME>Third post-operative day</NAME>
<CONT_DATA CI_END="-3.8333556930173813" CI_START="-282.1666443069826" EFFECT_SIZE="-143.0" ESTIMABLE="YES" MEAN_1="201.0" MEAN_2="344.0" MODIFIED="2008-06-20 18:05:39 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="331" SD_1="275.0" SD_2="275.0" SE="71.00469468046931" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="89.81900423794028"/>
<CONT_DATA CI_END="426.45476745582516" CI_START="-576.4547674558252" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="177.0" MEAN_2="252.0" MODIFIED="2008-06-22 06:21:02 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="327" SD_1="510.0" SD_2="1140.0" SE="255.848970394985" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="6.917911748590986"/>
<CONT_DATA CI_END="730.1383256337624" CI_START="-730.1383256337624" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="183.0" MEAN_2="183.0" MODIFIED="2008-06-20 16:37:28 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="315" SD_1="281.0" SD_2="2150.0" SE="372.52639915478056" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="3.2630840134687387"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.45192636038471373" CI_END="23.68586519305731" CI_START="-31.031696065594545" DF="3.0" EFFECT_SIZE="-3.6729154362686165" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.04" MODIFIED="2008-06-22 06:25:23 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.9293186943171418" P_Z="0.7924541562943089" STUDIES="4" TAU2="0.0" TOTAL_1="131" TOTAL_2="139" WEIGHT="99.99999999999999" Z="0.2631251030841382">
<NAME>Seventh post-operative day</NAME>
<CONT_DATA CI_END="53.909078712899614" CI_START="-97.90907871289961" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="60.0" MEAN_2="82.0" MODIFIED="2008-06-20 18:07:53 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="332" SD_1="150.0" SD_2="150.0" SE="38.72983346207417" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="12.989906742222653"/>
<CONT_DATA CI_END="77.60555854519032" CI_START="-67.60555854519032" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="44.0" MODIFIED="2008-06-22 06:25:23 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="328" SD_1="100.0" SD_2="150.0" SE="37.044333017286895" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="14.198868359815652"/>
<CONT_DATA CI_END="30.012530615956237" CI_START="-40.01253061595624" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="55.0" MODIFIED="2008-06-20 16:38:50 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="317" SD_1="70.0" SD_2="70.0" SE="17.863864281247313" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="61.058547820585744"/>
<CONT_DATA CI_END="92.80467539168379" CI_START="-66.80467539168379" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="168.0" MEAN_2="155.0" ORDER="180" SD_1="196.0" SD_2="213.0" SE="40.717419310340844" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="11.752677077375942"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="42.565037221524534" CI_END="8.979594524874836" CI_START="-18.81439398744331" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.917399731284236" ESTIMABLE="YES" I2="64.75980997753078" I2_Q="65.69697799432362" ID="CMP-001.11" MODIFIED="2008-06-22 06:29:57 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="11" P_CHI2="1.8388329593144181E-4" P_Q="0.032871970643973736" P_Z="0.48797954098063867" Q="8.74558515428631" RANDOM="NO" SCALE="895.11" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="466" TOTAL_2="481" UNITS="" WEIGHT="400.0" Z="0.6935259663529448">
<NAME>ALT (IU/L)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.99292330026681" CI_END="168.90359113857642" CI_START="-10.067919488941271" DF="4.0" EFFECT_SIZE="79.41783582481757" ESTIMABLE="YES" I2="59.9716731550096" ID="CMP-001.11.01" MODIFIED="2008-06-22 06:26:30 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.040547137093180474" P_Z="0.08195544174385984" STUDIES="5" TAU2="0.0" TOTAL_1="141" TOTAL_2="144" WEIGHT="100.0" Z="1.7394511271764892">
<NAME>First post-operative day</NAME>
<CONT_DATA CI_END="663.0907871289961" CI_START="-855.0907871289961" EFFECT_SIZE="-96.0" ESTIMABLE="YES" MEAN_1="826.0" MEAN_2="922.0" MODIFIED="2008-06-20 18:27:59 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="341" SD_1="1500.0" SD_2="1500.0" SE="387.2983346207417" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.3896978166967968"/>
<CONT_DATA CI_END="214.1562009868938" CI_START="23.84379901310622" EFFECT_SIZE="119.0" ESTIMABLE="YES" MEAN_1="313.0" MEAN_2="194.0" ORDER="165" SD_1="127.0" SD_2="61.0" SE="48.54997425334024" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" WEIGHT="88.43692355204254"/>
<CONT_DATA CI_END="-130.74638705251908" CI_START="-1073.2536129474809" EFFECT_SIZE="-602.0" ESTIMABLE="YES" MEAN_1="333.0" MEAN_2="935.0" MODIFIED="2008-06-22 06:26:30 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="164" SD_1="824.0" SD_2="824.0" SE="240.43993495016707" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="3.605773400648348"/>
<CONT_DATA CI_END="452.2763895862346" CI_START="-1092.2763895862345" EFFECT_SIZE="-320.0" ESTIMABLE="YES" MEAN_1="444.0" MEAN_2="764.0" MODIFIED="2008-06-20 16:43:47 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="319" SD_1="1544.0" SD_2="1544.0" SE="394.0258064320835" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="1.342648407753197"/>
<CONT_DATA CI_END="420.4826822031454" CI_START="-362.4826822031454" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="706.0" MEAN_2="677.0" ORDER="163" SD_1="1030.0" SD_2="976.0" SE="199.73973261300247" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="5.224956822859111"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.256103928889145" CI_END="180.87783940481165" CI_START="-4.239139050568923" DF="3.0" EFFECT_SIZE="88.31935017712136" ESTIMABLE="YES" I2="78.95638236811196" ID="CMP-001.11.02" MODIFIED="2008-06-22 06:27:34 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="0.0025764933336124285" P_Z="0.061456261297282655" STUDIES="4" TAU2="0.0" TOTAL_1="113" TOTAL_2="110" WEIGHT="100.0" Z="1.8701984758989865">
<NAME>Second post-operative day</NAME>
<CONT_DATA CI_END="253.06052475266415" CI_START="-759.0605247526642" EFFECT_SIZE="-253.0" ESTIMABLE="YES" MEAN_1="809.0" MEAN_2="1062.0" MODIFIED="2008-06-20 18:29:13 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="342" SD_1="1000.0" SD_2="1000.0" SE="258.19888974716116" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.3452423914950797"/>
<CONT_DATA CI_END="262.8512137441285" CI_START="33.1487862558715" EFFECT_SIZE="148.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="227.0" ORDER="168" SD_1="136.0" SD_2="89.0" SE="58.598634796384125" STUDY_ID="STD-Bombuy-2004" TOTAL_1="10" TOTAL_2="5" WEIGHT="64.94733514852506"/>
<CONT_DATA CI_END="-176.11485965806116" CI_START="-921.8851403419388" EFFECT_SIZE="-549.0" ESTIMABLE="YES" MEAN_1="492.0" MEAN_2="1041.0" MODIFIED="2008-06-22 06:27:34 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="166" SD_1="652.0" SD_2="652.0" SE="190.25101648969533" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="6.16144194637222"/>
<CONT_DATA CI_END="318.1280913549277" CI_START="-48.128091354927676" EFFECT_SIZE="135.0" ESTIMABLE="YES" MEAN_1="385.0" MEAN_2="250.0" ORDER="167" SD_1="555.0" SD_2="362.0" SE="93.43441655021148" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="25.54598051360764"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8255648000464335" CI_END="37.85167618621089" CI_START="-160.25521558534157" DF="2.0" EFFECT_SIZE="-61.20176969956534" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.03" MODIFIED="2008-06-22 06:28:37 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="3" P_CHI2="0.40140584569806637" P_Z="0.2258972013347077" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="88" WEIGHT="100.0" Z="1.2109953705153005">
<NAME>Third post-operative day</NAME>
<CONT_DATA CI_END="336.06052475266415" CI_START="-676.0605247526642" EFFECT_SIZE="-170.0" ESTIMABLE="YES" MEAN_1="644.0" MEAN_2="814.0" MODIFIED="2008-06-20 18:29:40 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="343" SD_1="1000.0" SD_2="1000.0" SE="258.19888974716116" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.8311949703811385"/>
<CONT_DATA CI_END="109.73728654256718" CI_START="-809.7372865425672" EFFECT_SIZE="-350.0" ESTIMABLE="YES" MEAN_1="386.0" MEAN_2="736.0" MODIFIED="2008-06-22 06:28:37 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="325" SD_1="1010.0" SD_2="506.0" SE="234.56415024404336" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="4.642155888791389"/>
<CONT_DATA CI_END="61.537054821470576" CI_START="-145.53705482147058" EFFECT_SIZE="-42.0" ESTIMABLE="YES" MEAN_1="421.0" MEAN_2="463.0" MODIFIED="2008-06-20 16:44:06 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="318" SD_1="207.0" SD_2="207.0" SE="52.825998660259906" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="91.52664914082747"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.744860038035839" CI_END="6.221798821254167" CI_START="-22.542740412664656" DF="3.0" EFFECT_SIZE="-8.160470795705246" ESTIMABLE="YES" I2="61.26463247538783" ID="CMP-001.11.04" MODIFIED="2008-06-22 06:29:57 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.05158981314021316" P_Z="0.26610393850271274" STUDIES="4" TAU2="0.0" TOTAL_1="131" TOTAL_2="139" WEIGHT="99.99999999999999" Z="1.1120796148622456">
<NAME>Seventh post-operative day</NAME>
<CONT_DATA CI_END="-9.272790692922001" CI_START="-798.727209307078" EFFECT_SIZE="-404.0" ESTIMABLE="YES" MEAN_1="918.0" MEAN_2="1322.0" ORDER="344" SD_1="780.0" SD_2="780.0" SE="201.39513400278568" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.13275800686939215"/>
<CONT_DATA CI_END="-6.367464994745049" CI_START="-151.63253500525497" EFFECT_SIZE="-79.0" ESTIMABLE="YES" MEAN_1="119.0" MEAN_2="198.0" MODIFIED="2008-06-22 06:29:57 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="326" SD_1="127.0" SD_2="127.0" SE="37.05809677023206" STUDY_ID="STD-Cescon-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="3.9209603248801814"/>
<CONT_DATA CI_END="18.50877143116936" CI_START="-30.50877143116936" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="217.0" MEAN_2="223.0" MODIFIED="2008-06-20 16:44:22 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="320" SD_1="49.0" SD_2="49.0" SE="12.504704996873118" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="34.43592622837704"/>
<CONT_DATA CI_END="14.338056551130023" CI_START="-22.338056551130023" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="41.0" ORDER="169" SD_1="27.0" SD_2="61.0" SE="9.356323226231845" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="61.51035543987337"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.108576446371088" CI_END="0.14425952705444534" CI_START="-0.7445125750464151" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3001265239959849" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-06-20 18:16:08 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="12" P_CHI2="0.9041219499768033" P_Q="0.6397115833594862" P_Z="0.18560018484045365" Q="1.6875219712218836" RANDOM="NO" SCALE="4.29637443085379" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="354" TOTAL_2="375" UNITS="" WEIGHT="400.0" Z="1.3237075656332244">
<NAME>Bilirubin (mg/dL)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2903928430522393" CI_END="0.11717758961188507" CI_START="-1.6992955298855712" DF="2.0" EFFECT_SIZE="-0.791058970136843" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2008-06-20 18:11:57 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.5245595271353042" P_Z="0.08780419146890991" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="99.99999999999999" Z="1.7070961023023605">
<NAME>First post-operative day</NAME>
<CONT_DATA CI_END="-0.0372728980194057" CI_START="-2.1627271019805945" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.6" MODIFIED="2008-06-20 18:11:57 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="333" SD_1="2.1" SD_2="2.1" SE="0.5422176684690383" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="73.03893755016068"/>
<CONT_DATA CI_END="3.051235160715686" CI_START="-3.8512351607156865" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.7" MODIFIED="2008-06-20 16:48:18 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="322" SD_1="6.9" SD_2="6.9" SE="1.7608666220086637" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="6.9254636641256475"/>
<CONT_DATA CI_END="2.2290736761193295" CI_START="-1.82907367611933" EFFECT_SIZE="0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.2" ORDER="183" SD_1="5.0" SD_2="5.4" SE="1.0352606946476588" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="20.035598785713667"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.31229907228804976" CI_END="1.669162857146479" CI_START="-1.370127310163839" DF="1.0" EFFECT_SIZE="0.14951777349131995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2008-06-20 18:14:21 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="0.5762729092608683" P_Z="0.8470837126420667" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="81" WEIGHT="100.0" Z="0.19284071935187738">
<NAME>Second post-operative day</NAME>
<CONT_DATA CI_END="2.436363148515985" CI_START="-3.636363148515984" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.3" MODIFIED="2008-06-20 18:14:21 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="334" SD_1="6.0" SD_2="6.0" SE="1.5491933384829668" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="25.048222650868006"/>
<CONT_DATA CI_END="2.1552993882419633" CI_START="-1.3552993882419637" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.9" ORDER="184" SD_1="4.5" SD_2="4.5" SE="0.8955773688126625" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="74.95177734913199"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.49823454705315895" CI_END="0.5585290227433667" CI_START="-0.8270788392199969" DF="1.0" EFFECT_SIZE="-0.13427490823831512" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.03" MODIFIED="2008-06-20 18:15:39 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="3" P_CHI2="0.4802769270730728" P_Z="0.70404346679967" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="64" WEIGHT="100.0" Z="0.37986791414651594">
<NAME>Third post-operative day</NAME>
<CONT_DATA CI_END="0.6121210495053282" CI_START="-1.412121049505328" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.9" MODIFIED="2008-06-20 18:15:39 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="335" SD_1="2.0" SD_2="2.0" SE="0.5163977794943222" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="46.854981647663045"/>
<CONT_DATA CI_END="1.0503401167188122" CI_START="-0.8503401167188119" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.7" MODIFIED="2008-06-20 16:48:37 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="321" SD_1="1.9" SD_2="1.9" SE="0.48487631620528415" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="53.14501835233696"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.32012801275575625" CI_END="0.6064465820301432" CI_START="-1.1244621293935753" DF="2.0" EFFECT_SIZE="-0.25900777368171607" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.04" MODIFIED="2008-06-20 18:16:08 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.8520892684415466" P_Z="0.5574953746418754" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.0" Z="0.5865657787515698">
<NAME>Seventh post-operative day</NAME>
<CONT_DATA CI_END="1.6254542039611888" CI_START="-2.625454203961189" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.9" MODIFIED="2008-06-20 18:16:08 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="336" SD_1="4.2" SD_2="4.2" SE="1.0844353369380766" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.58001168319069"/>
<CONT_DATA CI_END="1.2466015234309222" CI_START="-1.2466015234309222" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="1.8" MODIFIED="2008-06-20 16:48:58 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="323" SD_1="2.4" SD_2="2.6" SE="0.6360328726772307" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="48.19844526365678"/>
<CONT_DATA CI_END="0.9582768409868851" CI_START="-1.9582768409868851" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.4" ORDER="185" SD_1="4.2" SD_2="3.2" SE="0.7440324681930824" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="35.22154305315253"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.374342287089172" CI_END="0.00840555478477259" CI_START="-0.2837740140473245" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.13768422963127597" ESTIMABLE="YES" I2="13.247512459652848" I2_Q="37.62965120214118" ID="CMP-001.13" MODIFIED="2008-07-01 12:06:01 +0100" MODIFIED_BY="dimitrinka nikolova" NO="13" P_CHI2="0.32103851419668017" P_Q="0.18625225788953437" P_Z="0.06471907023785085" Q="4.809977910694305" RANDOM="NO" SCALE="1.26" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="354" TOTAL_2="375" UNITS="" WEIGHT="400.0" Z="1.8471937130656664">
<NAME>Prothrombin time (percentage activity/INR)</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>Controls</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3077713734112215" CI_END="0.06134161018900569" CI_START="-0.46659486023864677" DF="2.0" EFFECT_SIZE="-0.20262662502482054" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2008-06-20 18:18:49 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.5200212398899997" P_Z="0.1324520130099509" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.00000000000001" Z="1.504502566514674">
<NAME>First post-operative day</NAME>
<CONT_DATA CI_END="0.40768890022938165" CI_START="-0.6050914976319791" EFFECT_SIZE="-0.0987012987012987" ESTIMABLE="YES" MEAN_1="-58.0" MEAN_2="-55.0" MODIFIED="2008-06-20 18:18:29 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="337" SD_1="30.0" SD_2="30.0" SE="0.2583670939491856" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="27.172697559654434"/>
<CONT_DATA CI_END="0.052039034520220684" CI_START="-0.9619154837219728" EFFECT_SIZE="-0.454938224600876" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.0" MODIFIED="2008-06-20 18:18:45 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="171" SD_1="0.4" SD_2="0.8" SE="0.25866661995836077" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="27.109804114988606"/>
<CONT_DATA CI_END="0.2756218501171997" CI_START="-0.5051792844908856" EFFECT_SIZE="-0.11477871718684292" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.7" MODIFIED="2008-06-20 18:18:49 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="170" SD_1="0.7" SD_2="1.0" SE="0.19918762302954157" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="45.71749832535697"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6937575690956526" CI_END="0.4773516841689256" CI_START="-0.14335932469366297" DF="1.0" EFFECT_SIZE="0.1669961797376313" ESTIMABLE="YES" I2="40.95967343579579" ID="CMP-001.13.02" MODIFIED="2008-06-20 18:20:56 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="0.1931064634228714" P_Z="0.2916000887625798" STUDIES="2" TAU2="0.0" TOTAL_1="80" TOTAL_2="81" WEIGHT="99.99999999999999" Z="1.0546179886234086">
<NAME>Second post-operative day</NAME>
<CONT_DATA CI_END="0.40768890022938165" CI_START="-0.6050914976319791" EFFECT_SIZE="-0.0987012987012987" ESTIMABLE="YES" MEAN_1="-69.0" MEAN_2="-66.0" MODIFIED="2008-06-20 18:20:56 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="338" SD_1="30.0" SD_2="30.0" SE="0.2583670939491856" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="37.56196657974417"/>
<CONT_DATA CI_END="0.7196034398139468" CI_START="-0.0659302941655665" EFFECT_SIZE="0.32683657282419015" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.3" MODIFIED="2008-06-20 18:19:14 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="175" SD_1="0.7" SD_2="0.5" SE="0.20039494097230948" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="62.43803342025581"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7421686305482531" CI_END="0.13416062610129154" CI_START="-0.580821988710155" DF="1.0" EFFECT_SIZE="-0.22333068130443173" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.03" MODIFIED="2008-06-20 18:21:04 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="3" P_CHI2="0.3889671031626888" P_Z="0.2207932339526537" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="64" WEIGHT="100.0" Z="1.22442163748251">
<NAME>Third post-operative day</NAME>
<CONT_DATA CI_END="0.4404062073154546" CI_START="-0.5720079389171862" EFFECT_SIZE="-0.0658008658008658" ESTIMABLE="YES" MEAN_1="-79.0" MEAN_2="-77.0" MODIFIED="2008-06-20 18:21:04 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="339" SD_1="30.0" SD_2="30.0" SE="0.25827366069438884" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="49.87404054362575"/>
<CONT_DATA CI_END="0.12486464754308974" CI_START="-0.885002240451048" EFFECT_SIZE="-0.3800687964539791" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.4" MODIFIED="2008-06-20 18:19:18 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="172" SD_1="0.2" SD_2="0.3" SE="0.25762383797861566" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="50.12595945637424"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8206668033397404" CI_END="0.017601356041902105" CI_START="-0.511335099217304" DF="2.0" EFFECT_SIZE="-0.24686687158770093" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.04" MODIFIED="2008-06-20 18:21:38 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.4023900913735058" P_Z="0.0673215957494957" STUDIES="3" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="100.00000000000001" Z="1.8295210038069951">
<NAME>Seventh post-operative day</NAME>
<CONT_DATA CI_END="0.506060524752664" CI_START="-0.506060524752664" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="80.0" MEAN_2="80.0" MODIFIED="2008-06-20 18:21:38 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="340" SD_1="30.0" SD_2="30.0" SE="0.2581988897471611" STUDY_ID="STD-Amador-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="27.31128199868555"/>
<CONT_DATA CI_END="0.014452466494167149" CI_START="-1.0019001652389379" EFFECT_SIZE="-0.4937238493723854" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.3" MODIFIED="2008-06-20 18:19:23 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="173" SD_1="0.2" SD_2="0.2" SE="0.25927839484550863" STUDY_ID="STD-Koneru-2005" TOTAL_1="28" TOTAL_2="34" WEIGHT="27.084334491845084"/>
<CONT_DATA CI_END="0.14352355586041204" CI_START="-0.6397260875059809" EFFECT_SIZE="-0.24810126582278447" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.2" MODIFIED="2008-06-20 18:19:27 +0100" MODIFIED_BY="Kurinchi S Gurusamy" ORDER="174" SD_1="0.4" SD_2="0.4" SE="0.19981225408848485" STUDY_ID="STD-Koneru-2007" TOTAL_1="50" TOTAL_2="51" WEIGHT="45.60438350946938"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-06-20 18:25:26 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2">
<NAME>Methods of Ischaemic preconditioning</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-20 17:21:19 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Repeated stimuli</GROUP_LABEL_1>
<GROUP_LABEL_2>Single stimulus</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours repeated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-20 17:21:52 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Initial poor function (IPF)</NAME>
<GROUP_LABEL_1>Repeated stimuli</GROUP_LABEL_1>
<GROUP_LABEL_2>Single stimulus</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours repeated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-20 17:23:46 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft non function (PGNF)</NAME>
<GROUP_LABEL_1>Repeated stimuli</GROUP_LABEL_1>
<GROUP_LABEL_2>Single stimulus</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours repeated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-20 17:23:21 +0100" MODIFIED_BY="Kurinchi S Gurusamy" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Re-transplant</NAME>
<GROUP_LABEL_1>Repeated stimuli</GROUP_LABEL_1>
<GROUP_LABEL_2>Single stimulus</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours repeated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="0.0" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.8291994674693215" CI_END="291.7864706964664" CI_START="61.94842163972254" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="176.86744616809446" ESTIMABLE="YES" I2="45.331276452671965" I2_Q="45.331276452671965" ID="CMP-002.05" NO="5" P_CHI2="0.17622229538823175" P_Q="0.17622229538823175" P_Z="0.0025570690935259694" Q="1.8291994674693215" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="200.0" Z="3.0165051082682828">
<NAME>ALT (IU/L)</NAME>
<GROUP_LABEL_1>Repeated stimuli</GROUP_LABEL_1>
<GROUP_LABEL_2>Single stimulus</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours repeated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours controls</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1452216505198576E-32" CI_END="260.05170739572634" CI_START="-54.051707395726325" DF="0.0" EFFECT_SIZE="103.00000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.0" P_Z="0.1986480362495379" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.2854128984344872">
<NAME>First post-operative day</NAME>
<CONT_DATA CI_END="260.05170739572634" CI_START="-54.05170739572634" EFFECT_SIZE="103.0" ESTIMABLE="YES" MEAN_1="364.0" MEAN_2="261.0" ORDER="56" SD_1="98.0" SD_2="150.0" SE="80.12989454629277" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="430.60247706702455" CI_START="93.39752293297545" DF="0.0" EFFECT_SIZE="262.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="1.0" P_Z="0.002321484905359815" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="3.045688135088065">
<NAME>Second post-operative day</NAME>
<CONT_DATA CI_END="430.60247706702455" CI_START="93.39752293297545" EFFECT_SIZE="262.0" ESTIMABLE="YES" MEAN_1="506.0" MEAN_2="244.0" ORDER="57" SD_1="170.0" SD_2="90.0" SE="86.02325267042627" STUDY_ID="STD-Bombuy-2004" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Ischaemic preconditioning versus control, outcome: 1.5 Primary graft non function (PGNF).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgments about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhgAAAEZCAMAAADi7qwaAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-11-12 13:16:38 +0100" MODIFIED_BY="dimitrinka nikolova" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVUAAAGlCAIAAADF/PJgAAATU0lEQVR42u3dvY4dxRaG4S2REEzg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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-12 15:31:22 +0100" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2008-09-12 15:31:22 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2008-09-12 15:31:22 +0100" MODIFIED_BY="dimitrinka nikolova">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-01 12:06:17 +0100" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Period</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy used</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>June 2008.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(((occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle OR ((ischaemi* OR ischemi*) AND precondition*) AND (liver OR hepatic) AND (segmentectomy OR resection OR transplant* OR graft*)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2, 2008.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 ((occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle in All Fields in all products<BR/>#2 (ischaemi* OR ischemi*) AND precondition* in All Fields in all products<BR/>#3 MeSH descriptor Ischemic Preconditioning explode all trees in MeSH products<BR/>#4 MeSH descriptor Ischemia explode all trees in MeSH products<BR/>#5 (#1 OR #2 OR #3 OR #4)<BR/>#6 liver OR hepatic in All Fields in all products<BR/>#7 MeSH descriptor Liver explode all trees in MeSH products<BR/>#8 MeSH descriptor Liver Diseases explode all trees in MeSH products<BR/>#9 MeSH descriptor Liver Neoplasms explode all trees in MeSH products<BR/>#10 (#6 OR #7 OR #8 OR #9)<BR/>#11 segmentectomy OR resection OR transplant* OR graft* in All Fields in all products<BR/>#12 (#10 AND #11)<BR/>#13 MeSH descriptor Hepatectomy explode all trees in MeSH products<BR/>#14 MeSH descriptor Liver Transplantation explode all trees in MeSH products<BR/>#15 (#12 OR #13 OR #14)<BR/>#16 (#5 AND #15)<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE/PubMed</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1950 to June 2008.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>("Liver Transplantation"[MeSH] OR ((liver or hepatic) NEAR (transplant* OR graft*))) AND ((ischaemi* OR ischemi*) AND precondition*) OR "ischemic preconditioning"[MeSH Terms]) AND ((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) AND humans [mh])</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 1974 to June 2008.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 (occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter$ OR venous OR vein OR hepatic OR portal) OR pringle OR (ischaemi$ OR ischemi$) AND precondition$<BR/>2 REPERFUSION-INJURY#.DE. OR ISCHEMIC-PRECONDITIONING#.DE. OR ISCHEMIA#.W..DE.<BR/>3 1 OR 2<BR/>4 LIVER OR HEPATIC OR HEPATO<BR/>5 SEGMENTECTOMY OR RESECTION<BR/>6 4 AND 5<BR/>7 HEPATECTOMY OR LIVER-RESECTION.DE.<BR/>8 6 OR 7<BR/>9 3 AND 8<BR/>10 RANDOM$ OR FACTORIAL$ OR CROSSOVER$ OR CROSS ADJ OVER$ OR PLACEBO$ OR DOUBL$ ADJ BLIND$ OR SINGL$ ADJ BLIND$ OR ASSIGN$ OR ALLOCAT$ OR VOLUNTEER$ OR CROSSOVER-PROCEDURE#.MJ. OR DOUBLE-BLIND-PROCEDURE#.DE. OR SINGLE-BLIND-PROCEDURE#.DE. OR RANDOMIZED-CONTROLLED-TRIAL#.DE.<BR/>11 9 AND 10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://portal.isiknowledge.com/portal.cgi?DestApp=WOS&amp;Func=Frame)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1970 to June 2008.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 TS=(((occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle)<BR/>#2 TS=((ischaemi* OR ischemi*) AND precondition*)<BR/>#3 #2 OR #1<BR/>#4 TS=(liver OR hepatic)<BR/>#5 TS=(segmentectomy OR resection OR transplant* OR graft*)<BR/>#6 #5 AND #4<BR/>#7 #6 AND #3<BR/>#8 TS=(random* OR blind*OR placebo* OR meta-analysis)<BR/>#9 #8 AND #7</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>